Flerie
NET ASSET VALUE – 31 August 2025
MARKN.
On the 31 August 2025 Flerie AB's Net Asset Value (NAV) was SEK 3,899 million and NAV per share was SEK 50.34.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 448 | 5.78 | 11.5% |
| Xspray Pharma | 18% | 308 | 3.98 | 7.9% |
| Empros Pharma | 79% | 204 | 2.64 | 5.2% |
| Atrogi | 44% | 197 | 2.54 | 5.0% |
| KAHR Medical | 30% | 179 | 2.31 | 4.6% |
| Lipum | 57% | 157 | 2.03 | 4.0% |
| Xintela | 59% | 148 | 1.91 | 3.8% |
| Goldcup 37076 (previously Toleranzia) | 100% | 131 | 1.69 | 3.4% |
| Microbiotica | 10% | 128 | 1.65 | 3.3% |
| Geneos Therapeutics | 12% | 91 | 1.18 | 2.3% |
| Mendus | 23% | 86 | 1.11 | 2.2% |
| AnaCardio | 13% | 79 | 1.02 | 2.0% |
| EpiEndo Pharmaceuticals | 9% | 55 | 0.71 | 1.4% |
| Vitara Biomedical | 11% | 47 | 0.61 | 1.2% |
| Buzzard Pharmaceuticals | 14% | 32 | 0.41 | 0.8% |
| Egetis Therapeutics | 1% | 25 | 0.32 | 0.6% |
| Amarna Therapeutics | 58% | 11 | 0.14 | 0.3% |
| Strike Pharma | 18% | 11 | 0.14 | 0.3% |
| Alder Therapeutics | 30% | 8 | 0.10 | 0.2% |
| Synerkine Pharma | 44% | 0 | 0.00 | 0.0% |
| Sixera Pharma | 35% | 0 | 0.00 | 0.0% |
| Total | 2,344 | 30.26 | 60.1% | |
| Commercial Growth | ||||
| NorthX Biologics | 61% | 202 | 2.61 | 5.2% |
| Symcel | 30% | 192 | 2.48 | 4.9% |
| Chromafora | 30% | 73 | 0.94 | 1.9% |
| Nanologica | 44% | 56 | 0.72 | 1.4% |
| Frontier Biosolutions | 2% | 18 | 0.24 | 0.5% |
| Bohus Biotech | 45% | 17 | 0.22 | 0.4% |
| Total | 558 | 7.20 | 14.3% | |
| Limited Partnerships, total | 106 | 1.37 | 2.7% | |
| Assets related to Portfolio companies | 301 | 3.89 | 7.7% | |
| Other assets and liabilities | 590 | 7.62 | 15.1% | |
| Net Asset Value | 3,899 | 50.34 | 100.0 | |
| Datum | 2025-09-03, kl 08:00 |
| Källa | MFN |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!